Search results
Author(s):
Michelle O'Donoghue
Added:
2 years ago
ESC 23 — Dr Michelle O'Donoghue (Brigham and Women's Hospital, US) outlines a trial update from OCEAN(a)-Dose Extension trial (NCT05581303) in this succinct interview.
OCEAN(a)-DOSE (Amgen) was a dose-finding study aiming to evaluate a siRNA, olpasiran, and its effect on risk for coronary heart disease death, myocardial infarction or urgent coronary revascularization when administered…
View more
Author(s):
Harriette Van Spall
,
Isabelle Mahé
Added:
9 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Author(s):
Dirk Sibbing
,
Michael J Blaha
,
Rajinder Chawla
,
et al
Added:
1 year ago
Lukas Lehmkuhl
Research Area(s) / Expertise:
Author
Expertise
Added:
1 year ago
This week on Parallax, Dr Ankur Kalra welcomes Eric Radtke, Vice President at Worldwide Innovations & Technologies, Inc, and Barbara Breininger, a cardiovascular radiologic technologist and clinical manager with 26 years of experience.This special episode dives deep into the crucial topic of radiation hygiene, exploring it from the perspectives of both manufacturers and users of radiation safety…
View more
Michael D Stubblefield
Author
William G Breen
Author
Author(s):
Steven E Nissen
Added:
9 months ago
ACC 2025 - 540-day follow up of lepodisiran in patients with elevated lipoprotein(a) (Lp(A)) shows the extended duration of action of lepodisiran will allow infrequent dosing in the ongoing cardiovascular outcome trial.Dr Steven Nissen (Cleveland Clinic, Cleveland, US) joins us onsite at ACC to discuss the ALPACA phase 2 trial (NCT05565742), investigating the safety and efficacy of lepodisiran,…
View more
Author(s):
Shozo Sueda
,
Tomoki Sakaue
Added:
1 year ago
Author(s):
Neha Pagidipati
Added:
4 months ago
ESC Congress 2025 - KARDIA 3 finds that a single dose of zilebesiran 300mg reduced office systolic blood pressure at month three compared to placebo, informing the dose, design and patient population for the upcoming zilebesiran phase III Cardiovascular outcomes trial.Dr Neha Pagidipati (Duke University Medical Center, US) joins us to discuss findings from the KARDIA-3 trial, evaluating…
View more